Skip to content
The Nexus
DossierENTITY

SUPPRESS-EARLY trial

Coverage of SUPPRESS-EARLY trial in the Nexus archive.

Earliest in view: Jun 29 · 15:57 UTCMost recent: Jun 29 · 15:57 UTC
Co-mentioned in this coverage
tirzepatidetopic1Mounjaroorganization1Zepboundorganization1type 2 diabetestopic1American Diabetes Associationorganization1MedPage Todayorganization1
Recent coverage
  • HEALTHJun 29 · 15:57 UTCMEDPAGE TODAY
    Could Early Tirzepatide Alter the Course of Type 2 Diabetes?

    2-year results from the SUPPRESS-EARLY trial indicate that early use of tirzepatide (Mounjaro, Zepbound) in type 2 diabetes management significantly improves outcomes. The findings were presented at the American Diabetes Association annual meeting.

SUPPRESS-EARLY trial · Dossier · The Nexus